Precision BioSciences' mission is to translate the world's most powerful genome editing technology into greatly needed products throughout the life sciences. Precision's proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/11/15 | $25,600,000 | Series A |
Amgen Business Development Baxter Ventures Longevity Fund VenBio | undisclosed |
| 06/28/18 | $110,000,000 | Series B |
Adage Capital Management Alexandria Real Estate Equities ArrowMark Partners  Brace Pharma Cormorant Asset Management Cowen Investments Franklin Templeton Gilead Sciences Osage University Partners Pontifax AgTech Ridgeback Capital Management Vivo Capital | undisclosed |
| 09/03/24 | $13,000,000 | Convertible Note |
Imugene Limited | undisclosed |
